CliffBio
small molecule

TELMISARTAN AND AMLODIPINE

AMLODIPINE BESYLATE; TELMISARTAN

Loss of exclusivity—loss of exclusivity
CompanyAlembic →See this company's full patent-cliff portfolio

Drug detail

Brand nameTELMISARTAN AND AMLODIPINE
Active ingredientAMLODIPINE BESYLATE; TELMISARTAN
StrengthEQ 10MG BASE;80MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalNovember 2016
Marketing statusDISCN

More from Alembic

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.